Conclusions:
No differences between the 2 commercially available transfemoral TAVI devices were observed in VARC outcomes at 30 days and one year except for major vascular complications with ESV and need for PPM with MCV. A trend for less major strokes was observed with ESV. These results need to be confirmed in a randomized trial. .7% in the high-risk category. Thirty-day mortality was 4.7% overall with no differences according to risk stratification: according to STS from low to high risk respectively 4.3% vs. 3.5% vs. 6.7% (pϭ0.392), logistic EuroSCORE 3.7%-vs. 2.3%vs. 6.7% (pϭ0.167) and logistic EuroSCORE II 3.2% vs. 6.2% vs. 6.8% (pϭ0.307). The C statistic for 30 day mortality for STS, logistic EuroSCORE, and logistic EuroSCORE II were respectively 0.60, 0.66 and 0.62. All high-risk groups developed more acute kidney injury stage 3 ( in high-risk STS 16.8%, logistic EuroSCORE 14.8% and logistic EuroSCORE II 17.6%) and stroke was more frequent in the high-risk logistic Euro-SCORE II group (0% vs. 0.9% vs. 5.4%; pϭ0.001). Conclusions: None of the available surgical risk scores were predictors of 30-day mortality following TAVI. Moreover, the C statistics showed poor discriminative ability of the scores for 30 day mortality. New scores are needed to help risk stratify TAVI patients.
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The effect of inflammation on left ventricular function after trancatheter aortic valve implantation
Manolis Vavuranakis 1 , Maria Kariori 1 , Konstantinos Kalogeras 1 , Dimitrios Vrachatis 1 , Carmen Moldovan 1 , Konstantinos Aznaouridis 1 , Evangelia Gravia 1 , Christodoulos Stefanadis 1 1 1st Department of Cardiology, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece Background: Trancatheter aortic valve implantation (TAVI) is an emerging treatment option for inoperable or high risk patients. After the procedure, most of patients show significant improvement of left ventricular function. However, the recovery of left ventricle is not immediately observed to all patients while to some others, it is temporarily deteriorated. Furthermore, some patients may elevate the levels of CRP and white blood cells (WBC) after TAVI. Elevated CRP has been associated with reduced left ventricular function. Therefore, we hypothesized that inflammatory parameters may influence left ventricular recovery after TAVI. Methods: Data from consecutive patients who underwent TAVI were evaluated from an existed database. Blood samples were obtained before TAVI, 3 hours and daily for 5 days after the procedure. CRP as well as WBC were recorded. In addition, transthoracic echocardiogram was performed and obtained before TAVI and daily for 5 days after the procedure. Patients were separated into three groups according to left ventricle improvement (improved, unaffected, declined) . Results: Overall, data from 76 patients (80.37Ϯ5.36 years, 33 males (48.8%), AVA: 0.63Ϯ0.15 cm2) were analyzed. Out of them, in 29 patients (39.7%) LVEF improved, in 11 patients (15.1%) it declined and in 33 patients (45.2%) it remained unaffected. We performed ANNOVA test among three groups and we found significant differences between groups for CRPmax (pϽ0.01) and WBC1st day after (pϽ0.01). In particular, post-hoc analysis showed higher levels of CRPmax (70.2Ϯ49.28 vs. 120Ϯ22.36, pϽ0.01) and WBC1st day after (16333Ϯ4685 vs. 11748Ϯ3512, pϽ0.01) in patients with declined LVEF comparing to those with unaffected LVEF respectively. Similarly, post-hoc analysis recorded greater value for CRPmax (120Ϯ22.36 vs. 61.99Ϯ36.9, pϽ0.01) and WBC1st day after (16528Ϯ4890 vs. 10800Ϯ2687, pϽ0.01) in patients with declined LVEF when compared with those with improved LVEF. Conclusions: In conclusion, inflammation as detected by simple indices such WBC and CRP may be associated with left ventricular function after TAVI. 
